JW Asset Management’s Adverum Biotechnologies ADVM Stock Holding History

JW Asset Management’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-17,865	Closed	-$625K	–	23
2017 Q4	$625K	Hold	17,865	–	–	0.67%	19
2017 Q3	$652K	Hold	17,865	–	–	0.48%	24
2017 Q2	$447K	Hold	17,865	–	–	0.28%	28
2017 Q1	$482K	Hold	17,865	–	–	0.1%	32
2016 Q4	$519K	Sell	17,865 -1,127	-6%	-$36.8K	0.35%	26
2016 Q3	$781K	Hold	18,992	–	–	0.54%	23
2016 Q2	$600K	Hold	18,992	–	–	0.48%	24
2016 Q1	$982K	Buy	+18,992	New	+$1.06M	0.64%	24

Other funds holding ADVM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

JW Asset Management's ADVM Position: Q1 2018 in Review

JW Asset Management sold out of Adverum Biotechnologies (ADVM) in Q1 2018, closing a stake of 17,865 shares — an estimated $625K sold.

JW Asset Management first reported a position in ADVM in Q1 2016 and held it in 8 quarters. The position peaked at $982K in Q1 2016. 96 funds tracked by Wall St. Rank hold ADVM as of Q1 2018.

JW Asset Management reported no remaining Adverum Biotechnologies position as of Q1 2018 after selling out during the quarter.
JW Asset Management sold 17,865 Adverum Biotechnologies shares in Q1 2018, an estimated $625K.
JW Asset Management first reported a position in Adverum Biotechnologies in Q1 2016 and held it in 8 quarters.
JW Asset Management's Adverum Biotechnologies position peaked at $982K in Q1 2016.
96 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2018.

Based on JW Asset Management's 13F filing for Q1 2018, filed 11 May 2018.